Revised terminal half‐life of nonacog alfa as derived from extended sampling data: A real‐world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis

Nonacog alfa, a standard half‐life recombinant factor IX (FIX), is used as a prophylactic treatment in severe haemophilia B (SHB) patients. Its half‐life determined in clinical studies involving a limited sampling (72 h) was shown to be rather short. In our clinical practice, we suspected that its half‐life could have been underestimated.

[1]  A. Iorio,et al.  Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database , 2021, Journal of thrombosis and haemostasis : JTH.

[2]  E. Santagostino,et al.  WFH Guidelines for the Management of Hemophilia, 3rd edition , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  A. Iorio,et al.  Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS‐Hemo project , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  A. Iorio,et al.  Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates , 2017, Thrombosis and Haemostasis.

[5]  R. Labadie,et al.  Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B , 2017, Thrombosis and Haemostasis.

[6]  D. Stafford.  Extravascular FIX and coagulation , 2016, Thrombosis Journal.

[7]  J. Korth-Bradley,et al.  Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  K. Kuliczkowski,et al.  Once‐weekly prophylactic treatment vs. on‐demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  J. Korth-Bradley,et al.  Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B. , 2016, Clinical therapeutics.

[10]  Hesham S. Al-Sallami,et al.  Prediction of Fat-Free Mass in Children , 2015, Clinical Pharmacokinetics.

[11]  L. Valentino,et al.  Multicentre, randomized, open‐label study of on‐demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  J. Dumont,et al.  Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. , 2013, The New England journal of medicine.

[13]  K. A. Stafford,et al.  Evidence of clinically significant extravascular stores of factor IX , 2013, Journal of thrombosis and haemostasis : JTH.

[14]  S. Björkman.  Population pharmacokinetics of recombinant factor IX: implications for dose tailoring , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  T. Lissitchkov,et al.  Head‐to‐head comparison of the pharmacokinetic profiles of a high‐purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  P. Mannucci,et al.  Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  P. Monahan,et al.  Abnormal hemostasis in a knock‐in mouse carrying a variant of factor IX with impaired binding to collagen type IV , 2009, Journal of thrombosis and haemostasis : JTH.

[19]  L. Valentino,et al.  Reformulated BeneFix®: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.